

Infertility is when a couple of reproductive age is unable to conceive after a year or more of regular unprotected intercourse.
It can be primary if no pregnancy has ever occurred or secondary if pregnancy has occurred irrespective of the outcome.
Ovulation induction is part of the patient's management which aims to achieve development of a single follicle and subsequent ovulation in a woman with anovulation.
Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.